Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Sarcoma 1Osteosarcoma 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Bone Neoplasms 1

Interventions

Nivolumab 7cemiplimab 6Specimen Handling 5HhAntag691 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Biopsy 4sonidegib 3pembrolizumab 3CTLA-4 Antigen 3relatlimab 2prednylidene 2deltacortene 2daromun 2Surgical Procedures, Operative 2Standard of Care 2Prednisone 2Observation 2Aminolevulinic Acid 2tocilizumab 1talimogene laherparepvec 1poly ICLC 1flt3 ligand protein 1X-Rays 1Watchful Waiting 1Vitamin D 1Tomography, Optical Coherence 1Therapeutics 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × flt3 ligand protein × 1 year × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡